Pacira Pharma (PCRX) Announces FDA Acceptance of sNDA for EXPAREL Use in Pediatric Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Pacira Pharma (PCRX) Announces FDA Acceptance of sNDA for EXPAREL Use in Pediatric Patients

Pacira BioSciences Announces FDA Acceptance of sNDA for EXPAREL Use in Pediatric Patients

August 4, 2020 7:31 AM EDT

sNDA submission based on positive Phase 3 data supporting expansion of the EXPAREL label to include use in children aged six and over

PARSIPPANY, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced the U.S. Food and Drug Administration (FDA) has accepted the submission of its supplemental new drug application (sNDA) seeking expansion of the EXPAREL® (bupivacaine liposome injectable suspension) label to include single-dose infiltration to provide postsurgical analgesia in children aged six and over. The expected action date by the FDA... More